COVID 19 & vaccines: Development and practice
More infoarray:22 [ "pii" => "S2445146022000905" "issn" => "24451460" "doi" => "10.1016/j.vacune.2022.10.021" "estado" => "S300" "fechaPublicacion" => "2022-09-01" "aid" => "246" "copyrightAnyo" => "2022" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Vacunas. 2022;23 Supl 2:S121-S122" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:17 [ "pii" => "S2445146022000917" "issn" => "24451460" "doi" => "10.1016/j.vacune.2022.10.022" "estado" => "S300" "fechaPublicacion" => "2022-09-01" "aid" => "242" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Vacunas. 2022;23 Supl 2:S123-S124" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the editor</span>" "titulo" => "Early diagnosis and treatment of SARS-CoV-2 vaccination associated polyradiculitis improves outcome" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "S123" "paginaFinal" => "S124" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "El diagnóstico y el tratamiento precoz y de la polirradiculitis asociada a la vacuna frente al SARS-CoV-2 mejora el resultado" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Josef Finsterer, Fulvio A. Scorza" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Josef" "apellidos" => "Finsterer" ] 1 => array:2 [ "nombre" => "Fulvio A." "apellidos" => "Scorza" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2445146022000917?idApp=UINPBA00004N" "url" => "/24451460/00000023000000S2/v3_202404040650/S2445146022000917/v3_202404040650/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S2445146022000930" "issn" => "24451460" "doi" => "10.1016/j.vacune.2022.10.024" "estado" => "S300" "fechaPublicacion" => "2022-09-01" "aid" => "255" "documento" => "article" "crossmark" => 1 "subdocumento" => "ssu" "cita" => "Vacunas. 2022;23 Supl 2:S111-S120" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Vaccine strategies</span>" "titulo" => "Mass vaccinations against COVID-19 through the use of technologies for the management of appointment scheduling and data of large volumes of vaccinated" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "S111" "paginaFinal" => "S120" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Vacunaciones masivas contra el COVID-19 mediante el uso de las tecnologías para la gestión de la programación de citas y de datos de grandes volúmenes de vacunados" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "f0015" "etiqueta" => "Fig. 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 2125 "Ancho" => 2958 "Tamanyo" => 287550 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "al0015" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="sp0015" class="elsevierStyleSimplePara elsevierViewall">Dashboard in real time; it displays the process of mass vaccination.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Alicia K. Rodas-Martinez, Josue R. Altamirano-Yupanqui" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Alicia K." "apellidos" => "Rodas-Martinez" ] 1 => array:2 [ "nombre" => "Josue R." "apellidos" => "Altamirano-Yupanqui" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1576988722000735" "doi" => "10.1016/j.vacun.2022.07.003" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1576988722000735?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2445146022000930?idApp=UINPBA00004N" "url" => "/24451460/00000023000000S2/v3_202404040650/S2445146022000930/v3_202404040650/en/main.assets" ] "en" => array:15 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the editor</span>" "titulo" => "Recommendation of a fourth SARS-CoV-2 vaccine dosage in vulnerable individuals, yes or not?" "tieneTextoCompleto" => true "saludo" => "Dear Editor," "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "S121" "paginaFinal" => "S122" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Masoud Keikha" "autores" => array:1 [ 0 => array:4 [ "nombre" => "Masoud" "apellidos" => "Keikha" "email" => array:1 [ 0 => "keikham971@mums.ac.ir" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "af0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "af0010" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cr0005" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran" "etiqueta" => "a" "identificador" => "af0005" ] 1 => array:3 [ "entidad" => "Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran" "etiqueta" => "b" "identificador" => "af0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cr0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Recomendación de una cuarta dosis de vacuna frente a SARS-CoV-2 en individuos vulnerables: ¿sí o no?" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="p0005" class="elsevierStylePara elsevierViewall">Recent studies suggested that even three doses of the Moderna SARS-CoV-2 vaccine could not be able to elicit an adequate immune response in kidney transplant recipient cases.<a class="elsevierStyleCrossRef" href="#bb0005"><span class="elsevierStyleSup">1</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bb0010"><span class="elsevierStyleSup">2</span></a> Although administration of the Pfizer and AstraZeneca vaccines might able to provides a robust immune protective response against the alpha variant, the effectiveness of these vaccine against delta variant was three to five less than the alpha variant even in immunocompetent individuals.<a class="elsevierStyleCrossRef" href="#bb0015"><span class="elsevierStyleSup">3</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bb0020"><span class="elsevierStyleSup">4</span></a> However, the Israel's prime minister Naftali Bennett recommended the fourth dose of the COVID-19 vaccine to health-care workers and people older than 60 years on Jan 2, 2022. Previous reports revealed that seroconversion rate was about 50% in solid organ transplant recipients even after a third dose.<a class="elsevierStyleCrossRef" href="#bb0025"><span class="elsevierStyleSup">5</span></a> Thus, establishment of long-term immune response in immune-deficient population could be helpful in significant reduction in COVID-19 mortality rate in these vulnerable subjects. Till now, there is doubt about effectiveness of a fourth SARS-CoV-2 vaccine dose for immune-compromised patients.</p><p id="p0010" class="elsevierStylePara elsevierViewall">In recent, Kamar et al., investigated the effectiveness of a fourth dose of Pfizer BioNTech COVID-19 vaccine for recipients of a solid organ transplant in France, they found that a fourth SARS-CoV-2 vaccine dosage was elicit a slight upgraded humoral response in participants with a weak response after 3 doses but not in patients with no response after 3 doses.<a class="elsevierStyleCrossRef" href="#bb0030"><span class="elsevierStyleSup">6</span></a> Alejo et al. was showed that a fourth doses of SARS-CoV-2 vaccine could result increasing immune response in 50% of patients with negative as well as all solid organ transplant recipients with low-positive titers after 3 doses of the Pfizer or Moderna.<a class="elsevierStyleCrossRef" href="#bb0035"><span class="elsevierStyleSup">7</span></a> In addition, Benotmane et al., recently revealed the high portion (up to 80%) of kidney transplant recipients have a weak immune response after three doses. Meanwhile, a fourth dose of the Moderna vaccine cause to significant increase of neutralizing antibodies response against the delta variant.<a class="elsevierStyleCrossRef" href="#bb0040"><span class="elsevierStyleSup">8</span></a> Indeed, the evaluation of available documents exhibited that a four doses of SARS-CoV-2 vaccine appear to be increased both humoral and cellular-based immunity response event in immune-compromised patients with no response after 3 doses. The results of Abbasi et al. was confirmed the results of previous reports on the efficacy of a fourth SARS-CoV-2 mRNA-vaccine in promotion of immune-response in kidney transplant recipients who have a weak response after 3 doses.<a class="elsevierStyleCrossRef" href="#bb0045"><span class="elsevierStyleSup">9</span></a></p><p id="p0015" class="elsevierStylePara elsevierViewall">In summary, our report indicated the effectiveness of a fourth SARS-CoV-2 vaccine dose in immune-compromised individuals with a weak antibody response after three doses. In addition, the fourth booster vaccine was well tolerated. However, there is no knowledge regarding durability of antibody levels. On the other hand, seroconversion rate was varied among vulnerable subject with no response after three vaccine dosage. The implementation of hand hygiene, face masking, physical distancing, as well as administration of monoclonal antibodies could be efficient prophylaxis in immune-deficient patients with no response to three doses of SARS-CoV-2 vaccine.</p><span id="s0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0005">Conflict of interest</span><p id="p0020" class="elsevierStylePara elsevierViewall">None to declare.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:2 [ 0 => array:2 [ "identificador" => "s0005" "titulo" => "Conflict of interest" ] 1 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2022-03-12" "fechaAceptado" => "2022-06-03" "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bs0005" "bibliografiaReferencia" => array:9 [ 0 => array:3 [ "identificador" => "bb0005" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "I. Benotmane" 1 => "G. Gautier" 2 => "P. Perrin" 3 => "J. Olagne" 4 => "N. Cognard" 5 => "S. Fafi-Kremer" 6 => "S. Caillard" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jama.2021.12339" "Revista" => array:7 [ "tituloSerie" => "Jama." "fecha" => "2021" "volumen" => "326" "numero" => "11" "paginaInicial" => "1063" "paginaFinal" => "1065" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34297036" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bb0010" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:11 [ 0 => "V.G. Hall" 1 => "V.H. Ferreira" 2 => "T. Ku" 3 => "M. Ierullo" 4 => "B. Majchrzak-Kita" 5 => "C. Chaparro" 6 => "N. Selzner" 7 => "J. Schiff" 8 => "M. McDonald" 9 => "G. Tomlinson" 10 => "V. Kulasingam" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMc2111462" "Revista" => array:7 [ "tituloSerie" => "N Engl J Med" "fecha" => "2021" "volumen" => "385" "numero" => "13" "paginaInicial" => "1244" "paginaFinal" => "1246" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34379917" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bb0015" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:11 [ 0 => "D. Planas" 1 => "D. Veyer" 2 => "A. Baidaliuk" 3 => "I. Staropoli" 4 => "F. Guivel-Benhassine" 5 => "M.M. Rajah" 6 => "C. Planchais" 7 => "F. Porrot" 8 => "N. Robillard" 9 => "J. Puech" 10 => "M. Prot" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/s41586-021-03777-9" "Revista" => array:7 [ "tituloSerie" => "Nature." "fecha" => "2021" "volumen" => "596" "numero" => "7871" "paginaInicial" => "276" "paginaFinal" => "280" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34237773" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bb0020" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:11 [ 0 => "J.L. Bernal" 1 => "N. Andrews" 2 => "C. Gower" 3 => "E. Gallagher" 4 => "R. Simmons" 5 => "S. Thelwall" 6 => "J. Stowe" 7 => "E. Tessier" 8 => "N. Groves" 9 => "G. Dabrera" 10 => "R. Myers" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa2108891" "Revista" => array:7 [ "tituloSerie" => "N Engl J Med" "fecha" => "2021" "volumen" => "385" "numero" => "7" "paginaInicial" => "585" "paginaFinal" => "594" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34289274" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bb0025" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "W.A. Werbel" 1 => "B.J. Boyarsky" 2 => "M.T. Ou" 3 => "A.B. Massie" 4 => "A.A. Tobian" 5 => "J.M. Garonzik-Wang" 6 => "D.L. Segev" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.7326/L21-0282" "Revista" => array:7 [ "tituloSerie" => "Ann Intern Med" "fecha" => "2021" "volumen" => "174" "numero" => "9" "paginaInicial" => "1330" "paginaFinal" => "1332" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34125572" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bb0030" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Assessment of 4 Doses of SARS-CoV-2 Messenger RNA–Based Vaccine in Recipients of a Solid Organ Transplant" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "N. Kamar" 1 => "F. Abravanel" 2 => "O. Marion" 3 => "R. Romieu-Mourez" 4 => "C. Couat" 5 => "A. Del Bello" 6 => "J. Izopet" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "JAMA Netw Open" "fecha" => "2021" "volumen" => "4" "numero" => "11" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bb0035" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antibody response to a fourth dose of a SARS-CoV-2 vaccine in solid organ transplant recipients: a case series" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:11 [ 0 => "J.L. Alejo" 1 => "J. Mitchell" 2 => "T.P. Chiang" 3 => "A.T. Abedon" 4 => "B.J. Boyarsky" 5 => "R.K. Avery" 6 => "A.A. Tobian" 7 => "M.L. Levan" 8 => "A.B. Massie" 9 => "J.M. Garonzik-Wang" 10 => "D.L. Segev" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Transplantation." "fecha" => "2021" "volumen" => "105" "numero" => "12" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bb0040" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the delta variant in kidney transplant recipients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "I. Benotmane" 1 => "T. Bruel" 2 => "D. Planas" 3 => "S. Fafi-Kremer" 4 => "O. Schwartz" 5 => "S. Caillard" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "medRxiv." "fecha" => "2021" "volumen" => "101" "numero" => "5" "paginaInicial" => "1073" "paginaFinal" => "1076" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bb0045" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Fourth COVID-19 vaccine dose increases low antibodies" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "J. Abbasi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jama.2022.0327" "Revista" => array:6 [ "tituloSerie" => "JAMA." "fecha" => "2022" "volumen" => "327" "numero" => "6" "paginaInicial" => "517" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35133430" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/24451460/00000023000000S2/v3_202404040650/S2445146022000905/v3_202404040650/en/main.assets" "Apartado" => array:4 [ "identificador" => "66708" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Special Article" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/24451460/00000023000000S2/v3_202404040650/S2445146022000905/v3_202404040650/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2445146022000905?idApp=UINPBA00004N" ]